Biophytis

Biophytis Receivables

The Accounts Receivable of Biophytis (ALBPS.PA) as of Oct 30, 2026 is 82,000.00 EUR. In the previous year, Accounts Receivable was 297,000.00 EUR — a change of -72.39% (lower).

Receivables

82,000.00EUR

YoY

-72.39%

Last updated:

Accounts Receivable of Biophytis is 2024 82,000.00 EUR. Accounts Receivable of Biophytis was 2023 297,000.00 EUR. It decreases by -72.39% lower compared to the previous year.

The Biophytis Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
171,000.00 EUR
Jan 1, 2019
74,000.00 EUR
Jan 1, 2020
127,000.00 EUR
Jan 1, 2021
125,000.00 EUR
Jan 1, 2022
488,000.00 EUR
Jan 1, 2023
297,000.00 EUR
Jan 1, 2024
82,000.00 EUR
The Biophytis Receivables history
YEARReceivablesYoY
82,000.00EUR-72.39%
297,000.00EUR-39.14%
488,000.00EUR+290.40%
125,000.00EUR-1.57%
127,000.00EUR+71.62%
74,000.00EUR-56.73%
171,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biophytis Stock analysis

What does Biophytis do? Biophytis SA develops therapeutics for sarcopenia and Age Related Macular Degeneration, focusing on restoring muscular and visual functions. The company's clinical programs include Sarconeos (BIO101) for sarcopenia and Macuneos (BIO201) for ARMD, developed simultaneously in the U.S. and domestic markets. Biophytis generates revenue through clinical development partnerships and potential future product sales, targeting pharmaceutical companies and healthcare providers seeking treatments for aging-related conditions. The company's primary products are Sarconeos (BIO101) and Macuneos (BIO201), with clinical development ongoing for both. Biophytis targets healthcare providers and pharmaceutical companies as key buyers, particularly those focused on aging diseases. The firm's strategy involves advancing drug candidates through clinical trials to secure regulatory approvals and commercial partnerships. Biophytis SA's business model centers on the development of two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), for sarcopenia and ARMD respectively. The company's revenue streams are derived from clinical development collaborations and potential future licensing agreements with pharmaceutical firms. The target market comprises healthcare institutions and pharmaceutical companies seeking innovative treatments for age-related medical conditions. Biophytis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biophytis stock

Accounts Receivable of Biophytis is 82,000.00 EUR in 2024.

Accounts Receivable of Biophytis changed from 297,000.00 EUR to 82,000.00 EUR, representing a -72.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Biophytis since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Biophytis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biophytis

All Key Metrics — Biophytis